Tenecteplase: meta-analysis of COVID-19 studies

All studies   Mortality   Hospitalization   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 13 patientsc19early.org

Tenecteplase for COVID-19

Serious outcome risk
Tenecteplase
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−25%
Mortality (1)−25%
Hospitalization (1)15%
RCTs (1)−25%
Late (1)−25%
00.511.5+
← Tenecteplase
reduces riskIncreased
risk →
c19early.org
October 2026

Tenecteplase COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Poor (DB RCT)−25%1.25 · 0.15–10.46death2/81/5
Late treatment−25%1.25 · 0.15–10.462/81/525% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.85
All studies−25%1.25 · 0.15–10.462/81/525% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8500.511.52+
Rotate screen for more detailsIncrease width for more details
← Tenecteplase
reduces riskTenecteplase
increases risk →
c19early.org
October 2026

Tenecteplase COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Poor (DB RCT)−25%1.25 · 0.15–10.462/81/5
Late treatment−25%1.25 · 0.15–10.462/81/525% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.85
All studies−25%1.25 · 0.15–10.462/81/525% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8500.511.52+
Rotate screen for more detailsIncrease width for more details
← Tenecteplase
reduces riskTenecteplase
increases risk →
c19early.org
October 2026

Tenecteplase COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Poor (DB RCT)15%0.85 · 0.23–3.15hosp. time8 (n)5 (n)
Late treatment15%0.85 · 0.23–3.158 (n)5 (n)15% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.82
All studies15%0.85 · 0.23–3.158 (n)5 (n)15% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.8200.511.52+
Rotate screen for more detailsIncrease width for more details
← Tenecteplase
reduces riskTenecteplase
increases risk →
c19early.org
October 2026

Tenecteplase COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Poor (DB RCT)−25%1.25 · 0.15–10.46death2/81/5
Late treatment−25%1.25 · 0.15–10.462/81/525% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.85
All studies−25%1.25 · 0.15–10.462/81/525% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8500.511.52+
Rotate screen for more detailsIncrease width for more details
← Tenecteplase
reduces riskTenecteplase
increases risk →
c19early.org
October 2026

Tenecteplase COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Poor (DB RCT)−25%1.25 · 0.15–10.46death2/81/5
Late treatment−25%1.25 · 0.15–10.462/81/525% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.85
All studies−25%1.25 · 0.15–10.462/81/525% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8500.511.52+
Rotate screen for more detailsIncrease width for more details
← Tenecteplase
reduces riskTenecteplase
increases risk →
c19early.org
October 2026

Tenecteplase COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Poor (DB RCT)−25%1.25 · 0.15–10.462/81/5
Late treatment−25%1.25 · 0.15–10.462/81/525% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.85
All studies−25%1.25 · 0.15–10.462/81/525% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8500.511.52+
Rotate screen for more detailsIncrease width for more details
← Tenecteplase
reduces riskTenecteplase
increases risk →
c19early.org
October 2026

Tenecteplase COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Poor (DB RCT)−25%1.25 · 0.15–10.46death2/81/5
Late treatment−25%1.25 · 0.15–10.462/81/525% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.85
All studies−25%1.25 · 0.15–10.462/81/525% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.8500.511.52+
Rotate screen for more detailsIncrease width for more details
← Tenecteplase
reduces riskTenecteplase
increases risk →